ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/paediatric-and-aya/lymphoma-and-leukaemias
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Lymphoma and Leukaemias
22
trial(s) found.
NCT06876649
Paed
Phase 4
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
BTK inhibitor
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06514794
Paed
Phase 2
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex) (
WUC007-03
)
allogeneic CAR-T-cell therapy,CD7-targeting
Lymphoma
T-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
NCT06414148
Paed
Phase 2
Recruiting
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (
EpLCART
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06395103
Paed
Phase 1 / Phase 2
Recruiting
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (
9999-01A
)
anti-ROR1 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
Burkitt lymphoma
Diffuse large B-cell lymphoma
Ewing sarcoma
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT06137118
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (
SYRUS
)
bispecific T-cell engager,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05991388
Paed
Phase 2
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (
Glo-BNHL
)
Carboplatin
Dexamethasone
Etoposide
Ifosfamide
Loncastuximab Tesirine
Odronextamab
Rituximab
alkylating agent
anti-CD19 antibody-drug conjugate
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
cancer therapy
cancer therapy,CD19-targeting
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD19-targeting
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Non-Hodgkin's lymphoma
NCT05533775
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (
iMATRIX-GLO
)
bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05453903
Paed
Phase 1
Recruiting
A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations (
CR109124
)
KMT2A inhibitor
Acute myeloid leukaemia
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT05359237
Paed
Recruiting
A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods (
PEPN22P1
)
vinca alkaloid
Cancer
Lymphoma
Solid tumour
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT05327894
Paed
Phase 3
Recruiting
Interfant-21
International Collaborative Treatment Protocol for Infants Under One Year with KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Blinatumomab
Prednisone
bispecific T-cell engager,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
glucocorticoid
immuno-oncology therapy,CD19-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT05183035
Paed
Phase 3
Recruiting
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML (
ITCC-101-APAL2020D
)
Bcl2 inhibitor
anti-CD33 antibody-drug conjugate
antimetabolite
Acute myeloid leukaemia
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT04884035
Paed
Phase 1
Recruiting
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma (
CC-220-DLBCL-001
)
CELMoD agent
cereblon modulator
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
WA
6000 - Perth - Royal Perth Hospital (COMPLETED)
NCT04870944
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma (
PEPN2111
)
curaxin,FACT complex-targeting
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
H3K27M-mutant glioma
Lymphoma
Osteosarcoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
NCT04811560
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (
CR108998
)
KMT2A inhibitor
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Leukaemia
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04293562
Paed
Phase 3
Recruiting
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations (
AAML1831
)
AXL/FLT3 inhibitor
anti-CD33 antibody-drug conjugate
liposomal cytarabine/daunorubicin
Acute myeloid leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital (SUSPENDED)
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
QLD
4101 - South Brisbane - Queensland Children's Hospital (SUSPENDED)
WA
6009 - Perth - Perth Children's Hospital
NCT04094610
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations (
CA127-1029
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Central nervous system cancer
Lymphoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT03601442
Paed
Available
Managed Access Program (MAP) Cohort Treatment Plan
CCTL019B2003I
to Provide Access for Patients With Out of Specification Leukapheresis Product and/or Out of Specification Manufactured Tisagenlecleucel (CTL019; Kymriah®)
autologous CAR-T-cell therapy,CD19-targeting
Acute lymphoblastic leukaemia
Diffuse large B-cell lymphoma
WA
6150 - Murdoch - Fiona Stanley Hospital (AVAILABLE)
NCT03590171
Paed
Phase 2
Recruiting
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group (
IntReALL-HR-2010
)
Bortezomib
cancer therapy
cancer therapy,proteasome-targeting
proteasome inhibitor
Acute lymphoblastic leukaemia
VIC
3168 - Clayton - Monash Medical Centre
NCT03409081
Paed
No longer available
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) (
2215-CL-9200
)
AXL/FLT3 inhibitor
Acute myeloid leukaemia
ACT
2605 - Garran - The Canberra Hospital
NCT02724163
Paed
Phase 3
Recruiting
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy (
Myechild01
)
anti-CD33 antibody-drug conjugate
Acute myeloid leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT02670564
Paed
Phase 4
Recruiting
Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) (
NZ-2015-069--ZH-2014-0535
)
Busulfan
Treosulfan
alkylating agent
cancer therapy
cytotoxic chemotherapy
Acute lymphoblastic leukaemia
ACTRN12621000246886
Paed
Phase 2
Not yet recruiting
AMLM22/D3-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 3 is investigating the safety and efficacy of an Astrazeneca drug labelled AZD5153 as a maintenance therapy option. (
AMLM22-D3
)
BRD4 inhibitor
Acute myeloid leukaemia
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (19)
No longer available (1)
Not yet recruiting (1)
Recruitment Country and State
VIC (10)
WA (10)
QLD (9)
NSW (7)
SA (3)
NZ (2)
ACT (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (6)
Phase 2 (5)
Phase 3 (4)
Phase 4 (2)
Trial Type
Paed (22)
Cancer Therapy Class
CD20
18%
CD19
18%
CD33
14%
cereblon
9%
Bcl2
9%
DNA methyltransferase
9%
KMT2A
9%
AXL
9%
FLT3
9%
BTK
5%
CD7
5%
ROR1
5%
IL-6
5%
CD79b
5%
FACT complex
5%
ALK
5%
ROS1
5%
TRK
5%
proteasome
5%
BRD4
5%
Facility
4101 - South Brisbane - Queensland Children's Hospital (8)
2031 - Randwick - Sydney Children's Hospital (6)
6009 - Perth - Perth Children's Hospital (6)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
3052 - Parkville - Royal Children's Hospital Melbourne (4)
2145 - Westmead - The Children's Hospital at Westmead (4)
3168 - Clayton - Monash Medical Centre (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
3168 - Clayton - Monash Children's Hospital (2)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (2)
NZ.1023 - Grafton - Starship Children's Hospital (2)
6000 - Perth - Royal Perth Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
3004 - Melbourne, Southbank - Alfred Health (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
2605 - Garran - The Canberra Hospital (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Lymphoma
Lymphoid leukaemia
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Myeloid leukaemia
Non-Hodgkin's lymphoma
B-cell malignancy
Mature B-cell malignancy
Solid tumour
B-cell lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Neurological cancer
B-cell acute lymphoblastic leukaemia/lymphoma
Bone cancer
Sarcoma
Central nervous system cancer
Chronic lymphocytic leukaemia
T-cell acute lymphoblastic leukaemia/lymphoma
Burkitt lymphoma
Ewing family of tumours
Ewing sarcoma
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
Primitive neuroectodermal tumour
Mixed phenotype acute leukaemia
Diffuse intrinsic pontine glioma
Glioma
H3K27M-mutant glioma
High-grade glioma
Malignant glioma
Osteosarcoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy